drug
vortioxetine hydrobromide
Marketedupdated 5mo agoby Takeda Pharmaceuticals USA Inc
Approvedcommunity read0 votes
indications
investigational
Major Depression
all catalysts(0)
nothing on the calendar yet
Trials studying vortioxetine hydrobromide
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 17, 2026
71 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (80)
- Sep 21, 2032patentUS 9278096*PED
- Sep 21, 2032patentUS 9278096*PED
- Sep 21, 2032patentUS 9278096*PED
- Sep 21, 2032patentUS 9278096*PED
- Mar 21, 2032method-of-use (U-2436)US 9278096
- Mar 21, 2032method-of-use (U-2436)US 9278096
- Mar 21, 2032method-of-use (U-2436)US 9278096
- Mar 21, 2032method-of-use (U-2436)US 9278096
- Dec 30, 2031patentUS 8722684*PED
- Dec 30, 2031patentUS 8722684*PED
- Dec 30, 2031patentUS 8722684*PED
- Dec 30, 2031patentUS 8722684*PED
- Jun 30, 2031compositionUS 87226844.7y
- Jun 30, 2031compositionUS 87226844.7y
- Jun 30, 2031compositionUS 87226844.7y
- Jun 30, 2031compositionUS 87226844.7y
- Dec 15, 2027patentUS 11458134*PED1.2y
- Dec 15, 2027patentUS 11458134*PED1.2y
- Dec 15, 2027patentUS 11458134*PED1.2y
- Dec 15, 2027patentUS 11458134*PED1.2y
- Dec 15, 2027patentUS 8969355*PED1.2y
- Dec 15, 2027patentUS 8969355*PED1.2y
- Dec 15, 2027patentUS 8969355*PED1.2y
- Dec 15, 2027patentUS 8969355*PED1.2y
- Dec 15, 2027patentUS 9125908*PED1.2y
- Dec 15, 2027patentUS 9125908*PED1.2y
- Dec 15, 2027patentUS 9125908*PED1.2y
- Dec 15, 2027patentUS 9125908*PED1.2y
- Dec 15, 2027patentUS 9125909*PED1.2y
- Dec 15, 2027patentUS 9125909*PED1.2y
- Dec 15, 2027patentUS 9125909*PED1.2y
- Dec 15, 2027patentUS 9125909*PED1.2y
- Dec 15, 2027patentUS 9125910*PED1.2y
- Dec 15, 2027patentUS 9125910*PED1.2y
- Dec 15, 2027patentUS 9125910*PED1.2y
- Dec 15, 2027patentUS 9125910*PED1.2y
- Dec 15, 2027patentUS 9227946*PED1.2y
- Dec 15, 2027patentUS 9227946*PED1.2y
- Dec 15, 2027patentUS 9227946*PED1.2y
- Dec 15, 2027patentUS 9227946*PED1.2y
- Dec 15, 2027patentUS 9861630*PED1.2y
- Dec 15, 2027patentUS 9861630*PED1.2y
- Dec 15, 2027patentUS 9861630*PED1.2y
- Dec 15, 2027patentUS 9861630*PED1.2y
- Jun 15, 2027formulationUS 11458134251d
- Jun 15, 2027formulationUS 11458134251d
- Jun 15, 2027formulationUS 11458134251d
- Jun 15, 2027formulationUS 11458134251d
- Jun 15, 2027method-of-use (U-1668)US 8969355251d
- Jun 15, 2027method-of-use (U-1668)US 8969355251d
- Jun 15, 2027method-of-use (U-1668)US 8969355251d
- Jun 15, 2027method-of-use (U-1668)US 8969355251d
- Jun 15, 2027method-of-use (U-2309)US 9125908251d
- Jun 15, 2027method-of-use (U-2309)US 9125908251d
- Jun 15, 2027method-of-use (U-2309)US 9125908251d
- Jun 15, 2027method-of-use (U-2309)US 9125908251d
- Jun 15, 2027method-of-use (U-2309)US 9125909251d
- Jun 15, 2027method-of-use (U-2309)US 9125909251d
- Jun 15, 2027method-of-use (U-2309)US 9125909251d
- Jun 15, 2027method-of-use (U-2309)US 9125909251d
- Jun 15, 2027method-of-use (U-2309)US 9125910251d
- Jun 15, 2027method-of-use (U-2309)US 9125910251d
- Jun 15, 2027method-of-use (U-2309)US 9125910251d
- Jun 15, 2027method-of-use (U-2309)US 9125910251d
- Jun 15, 2027method-of-use (U-1668)US 9227946251d
- Jun 15, 2027method-of-use (U-1668)US 9227946251d
- Jun 15, 2027method-of-use (U-1668)US 9227946251d
- Jun 15, 2027method-of-use (U-1668)US 9227946251d
- Jun 15, 2027method-of-use (U-1668)US 9861630251d
- Jun 15, 2027method-of-use (U-1668)US 9861630251d
- Jun 15, 2027method-of-use (U-1668)US 9861630251d
- Jun 15, 2027method-of-use (U-1668)US 9861630251d
- Dec 17, 2026patentUS 7144884*PED71d
- Dec 17, 2026patentUS 7144884*PED71d
- Dec 17, 2026patentUS 7144884*PED71d
- Dec 17, 2026patentUS 7144884*PED71d
- Jun 17, 2026compositionUS 7144884
- Jun 17, 2026compositionUS 7144884
- Jun 17, 2026compositionUS 7144884
- Jun 17, 2026compositionUS 7144884
FDA exclusivities (8)
- Feb 23, 2027PEDPediatric (6mo bonus)139d
- Feb 23, 2027PEDPediatric (6mo bonus)139d
- Feb 23, 2027PEDPediatric (6mo bonus)139d
- Feb 23, 2027PEDPediatric (6mo bonus)139d
- Aug 23, 2026M-232Method (3y)
- Aug 23, 2026M-232Method (3y)
- Aug 23, 2026M-232Method (3y)
- Aug 23, 2026M-232Method (3y)
News(4)
- Adecto, Aviceda shut downFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 14h ago
- Out of sight, out of work? What’s driving remote job cutsBiopharma professionals sometimes find themselves out of jobs when employers want to bring staff back into the office, as recently seen at biotech EMD Serono and Exelixis.biospace · 1mo ago
- STAT+: Takeda will pay $13.6 million to settle allegations it paid kickbacks to doctorsTakeda Pharmaceuticals agreed to pay $13.6 million to settle allegations that it paid kickbacks to doctors to prescribe an antidepressant.stat · 4mo ago
- Fierce Biotech Layoff Tracker 2026: Foghorn cuts workforce by 40%; BioMarin drops 117 rolesAs always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.fiercebiotech · 9mo ago
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that